Insurance Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Insurance Press Releases.

Press releases published on October 24, 2026

Oct. 24, 2026

實時交易已融入客戶開戶注資的同一應用程式之中

Indeterminate GlobeNewswire

Oct. 24, 2026

AppLovin Corporation (APP) Class Action Lawsuit: Investors Face November 16, 2026, Deadline - Kessler Topaz Meltzer & Check, LLP

Indeterminate GlobeNewswire

Oct. 24, 2026

Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month

Indeterminate GlobeNewswire

Oct. 24, 2026

XTIA URGENT DEADLINE: Bragar Eagel & Squire, P.C. Urges XTI Aerospace, Inc. Investors to Contact the Firm Regarding Their Rights Before October 27th

Indeterminate GlobeNewswire

Oct. 24, 2026

JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value

Indeterminate GlobeNewswire

Oct. 24, 2026

XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt

Indeterminate GlobeNewswire

Oct. 24, 2026

XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux

Indeterminate GlobeNewswire

Oct. 24, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Lincoln Educational Services Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - LINC

Indeterminate GlobeNewswire

Oct. 24, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN

Indeterminate GlobeNewswire

Oct. 24, 2026

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

Indeterminate GlobeNewswire

Oct. 24, 2026

NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de de…

Indeterminate GlobeNewswire

Oct. 24, 2026

ROSEN, THE FIRST FILING FIRM, Encourages Netcapital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NCPL

Indeterminate GlobeNewswire

Oct. 24, 2026

Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks

Indeterminate GlobeNewswire

Oct. 24, 2026

ROSEN, THE FIRST FILING FIRM, Encourages Webull Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BULL

Indeterminate GlobeNewswire

Oct. 24, 2026

Alkanes borrningar bekräftar och utvidgar guld-antimon-mineralsystemet vid Nagambie i Victoria

Indeterminate GlobeNewswire

Oct. 24, 2026

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

Indeterminate GlobeNewswire

Oct. 24, 2026

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Indeterminate GlobeNewswire

Oct. 24, 2026

Tecnover Celebrates 41 Years of Italian Airless Spray-Painting Innovation

Indeterminate GlobeNewswire

Oct. 24, 2026

INTELLIGENCE, ENLIGHTENED: LUXEED Makes Its Global Debut, Redefining Luxury and Driving Pleasure Through Intelligence

Indeterminate GlobeNewswire

Oct. 24, 2026

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Indeterminate GlobeNewswire